Diamyd Medical

Pharmaceutical Manufacturing • Stockholm, Stockholm County, Sweden • 51-100 Employees

Company overview

Headquarters	Kungsgatan 29, Stockholm, SE-111 56, SE
Phone number	+4686610026
Website	diamyd.com
NAICS	3254
SIC	283
Keywords	Pharmaceutical Development, Autoimune Diabetes (Type 1 Diabetes And Lada), Pre-Clinical And Clinical Development, Preserving Beta Cell Function, Targeted Immunotherapy
Employees	51-100
Socials

Key Contacts at Diamyd Medical

Pedro F. Teixeira

Director Medical Affairs

Linnea Eriksson

Clinical Development Director

Diamyd Medical Email Formats

Diamyd Medical uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@diamyd.com), used 57.1% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@diamyd.com	57.1%
{first initial}.{last name}	j.doe@diamyd.com	38.1%
{first initial}	j@diamyd.com	4.8%

About Diamyd Medical

Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for the prevention and treatment of autoimmune diabetes. The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S. Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

Diamyd Medical revenue & valuation

Annual revenue	$760,784
Revenue per employee	$14,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$2,500,000
Total funding	$38,100,000